Sign in
Taking people in United StatesPhase 2

Tests blinatumomab and inotuzumab with chemotherapy for B-cell acute lymphoblastic leukemia

Tests immunotherapy with chemotherapy as first treatment in people with B-cell leukemia.

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Registry title
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
Status
Recruiting
Phase
Phase 2
People taking part
80 people, planned
Started
1 Nov 2016
Planned end
1 Nov 2026
Type of study
Interventional
Treatments tested
  • Blinatumomab
  • Cyclophosphamide
  • Cytarabine
  • Dexamethasone
  • Doxorubicin Hydrochloride
  • Inotuzumab Ozogamicin
  • Laboratory Biomarker Analysis
  • Mercaptopurine
  • Methotrexate
  • Ofatumumab
  • Prednisone
  • Rituximab
  • Vincristine Sulfate
Record updated
20 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 14 or older with B-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. They are newly diagnosed and untreated, in remission after one course of chemotherapy, or did not respond to one course.

Age
14 years and older
Sex
All sexes can join.
Disease stage
Newly diagnosed, previously untreated B-lineage ALL or lymphoblastic lymphoma, or complete remission after one induction chemotherapy course, or failure of one induction course (analyzed separately). Performance status of 0-3.
Earlier treatment
No prior treatment, except steroids, cytarabine or hydrea used to manage symptoms before the treatment plan is final. Or one course of induction chemotherapy.
Biomarker or test result
Philadelphia chromosome (Ph)-positive ALL is not allowed. Creatinine and bilirubin at or below 2.0 mg/dL (177 µmol/L), unless caused by the tumor.

Main reasons for not taking part

  • Pregnant or nursing women
  • Known to be HIV-positive
  • Philadelphia chromosome (Ph)-positive ALL
  • Active and uncontrolled disease or infection
  • History or presence of relevant brain or nerve disease, such as epilepsy, stroke or dementia

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Patients with newly diagnosed, previously untreated B-lineage ALL or lymphoblastic lymphoma, or having achieved complete remission (CR) with one course of induction chemotherapy; patients who require steroids, cytarabine (ara-c) or hydrea to manage disease symptoms prior to finalization of diagnosis and treatment plan are allowed and eligible
  • Failure to one induction course of chemotherapy (these patients will be analyzed separately); patients who require steroids, ara-c or hydrea to manage disease symptoms prior to finalization of diagnosis and treatment plan are allowed and eligible
  • Performance status of 0-3
  • Creatinine less than or equal to 2.0 mg/dL (unless considered tumor related)
  • Bilirubin less than or equal to 2.0 mg/dL (unless considered tumor related)
  • Adequate cardiac function as assessed by history and physical examination
  • No active or co-existing malignancy with life expectancy less than 12 months, sources for the determination of clinical significance by the treating physician will be included in the subject's medical record

Who cannot take part

  • Known to be human immunodeficiency virus (HIV)-positive
  • Active and uncontrolled disease/infection as judged by the treating physician, sources for the determination of clinical significance by the treating physician will be included in the subject's medical record
  • Subjects who have current active hepatic or biliary disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per treating physician assessment), sources for the determination of clinical significance by the treating physician will be included in the subject's medical record
  • History or presence of clinically relevant central nervous system (CNS) pathology such as epilepsy, childhood or adult seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis; (Patients with CNS involvement of leukemia are NOT excluded)
  • Current autoimmune disease or history of autoimmune disease with potential CNS involvement; auto-immune disease with possible CNS consequences/manifestations such as such as epilepsy, paresis, aphasia, stroke, dementia, Parkinson's disease, cerebellar disease, or psychosis
  • Pregnant or nursing women
  • Philadelphia chromosome (Ph)-positive ALL
  • Unable or unwilling to sign the consent form

Where in United States

  • M D Anderson Cancer CenterHouston, United StatesContact: Elias JabbourTaking people

About the trial

What the trial wants to find out

This phase II trial studies how well blinatumomab, inotuzumab ozogamicin, and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, cytarabine, mercaptopurine, methotrexate, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving blinatumomab, inotuzumab ozogamicin, and combination chemotherapy may work better in treating patients with B acute lymphoblastic leukemia than chemotherapy alone.

The group in the trial

  • Treatment (blinatumomab, inotuzumab, combination chemotherapy)Treatment being tested

    See detailed description.

    Treatment: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Laboratory Biomarker Analysis, Mercaptopurine, Methotrexate, Ofatumumab, Prednisone, Rituximab, and Vincristine Sulfate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia
Plain-language title
Tests blinatumomab and inotuzumab with chemotherapy for B-cell acute lymphoblastic leukemiaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Publications
Record updated
20 May 2026